How Psilocybin Clinical Trials Actually Work — From Phase 1 to FDA
Advertisement
About This Video
A clear explanation of how psilocybin clinical trials are structured — from Phase 1 safety to Phase 3 efficacy trials, what participants experience, and how the FDA evaluates the data.
Key Takeaways
- Phase 2 and 3 trials require double-blind design where feasible
- Participants receive extensive preparation and integration support
- FDA Breakthrough Therapy designation is accelerating the review pathway
Watch Next
Advertisement